Introduction to HER2 targets Human epidermal growth factor receptor 2 (HER2), also known as ERBB2, is a receptor tyrosine kinase that belongs to the ERBB receptor tyrosine kinase family together with HER1Read More…
02Dec/23
31Oct/23
Research progress on the application of EGFR single domain antibodies in tumor imaging
Single domain antibodies (sdAbs) are the smallest units that retain antigen-binding sites. They have the advantages of high antigen affinity, high specificity, high solubility, high stability, high clearance, low immunogenicity, and canRead More…
07Oct/23
Using single domain antibody targeted degradation technology to explore the subcellular functions of intracellular proteins
Protein degradation is an important mechanism by which organisms regulate the amount and activity of proteins in cells. The ubiquitin-proteasome system is involved in regulating important physiological or pathological processes such asRead More…
28Aug/23
Single Domain Antibody-Drug Conjugates
The development concept of single domain antibody-drug conjugates (sdAb-drug conjugates) is similar to that of antibody-drug conjugates (ADCs). That is, the antibody in the ADC is replaced with a single domain antibodyRead More…
01Aug/23
Single domain antibodies with flexible half-life
As a type of antibody with good application prospects, single domain antibodies have advantages in the diagnosis and treatment of many diseases. However, its short half-life in plasma limits its application inRead More…
01Jun/23
Advantages of Applying Single Domain Antibodies in the Field of Cell Therapy
Single domain antibodies have been widely used as antigen-binding domains in CAR-T due to their small size, excellent stability, high affinity, and strong manufacturing feasibility. Single domain antibody-based CAR constructs have shownRead More…
14Apr/23
Most Popular Antibody Fragment: Single Domain Antibody vs. ScFv
With the advent of recombinant DNA technology, many antibody fragments have been developed. Among them, camelid heavy chain variable domains (VHHs) and single chain variable domains (ScFv) are the most favored variableRead More…
07Sep/22
Molecular Therapy: Development of New-Generation of Fully Human Single-Domain Antibody-Drug Conjugates Targeting Solid Tumors
An antibody-drug conjugate (ADC) is formed by linking monoclonal antibodies and small molecule cytotoxic drugs through linkers. It has both the tumor targeting of antibody drugs and the strong tumor-killing activity ofRead More…
02Aug/22
Single-domain Antibodies and Undruggable Targets
The single-domain antibody has similar antigen binding characteristics to the traditional antibody. But, because single-domain antibodies use a single Ig variable domain for antigen recognition, they can access epitopes that cannot beRead More…
28Jun/22
Single Domain Antibodies and Specific Membrane Receptors (Blood-brain Barrier)
Single domain antibodies are derived from llama heavy chain-only antibodies (HCAbs). They represent a new generation of biologics with unique properties. Single domain antibodies have excellent tissue distribution, high temperature and pHRead More…